Small cell lung cancer: Difference between revisions
| Line 43: | Line 43: | ||
==Treatment== | ==Treatment== | ||
[[Small cell carcinoma of the lung medical therapy|Medical therapy]] | [[Small cell carcinoma of the lung surgery|Surgical options]] | [[Small cell carcinoma of the lung primary prevention|Primary prevention]] | [[Small cell carcinoma of the lung secondary prevention|Secondary prevention]] | [[Small cell carcinoma of the lung cost-effectiveness of therapy|Financial costs]] | [[Small cell carcinoma of the lung future or investigational therapies|Future therapies]] | [[Small cell carcinoma of the lung medical therapy|Medical therapy]] | [[Small cell carcinoma of the lung surgery|Surgical options]] | [[Small cell carcinoma of the lung primary prevention|Primary prevention]] | [[Small cell carcinoma of the lung secondary prevention|Secondary prevention]] | [[Small cell carcinoma of the lung cost-effectiveness of therapy|Financial costs]] | [[Small cell carcinoma of the lung future or investigational therapies|Future therapies]] | ||
==Prognostic factors== | ==Prognostic factors== | ||
Revision as of 16:54, 9 December 2011
For patient information click here
Template:DiseaseDisorder infobox
|
Small Cell Carcinoma of the Lung Microchapters |
|
Differentiating Small Cell Carcinoma of the Lung from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Small cell lung cancer On the Web |
|
American Roentgen Ray Society Images of Small cell lung cancer |
|
Directions to Hospitals Treating Small cell carcinoma of the lung |
|
Risk calculators and risk factors for Small cell lung cancer |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Synonyms and related keywords: Oat Cell Carcinoma, Reserve Cell Carcinoma, Round Cell Carcinoma, Small Cell Lung Carcinoma, Small Cell Lung Cancer
Overview
Historical Perspective
Pathophysiology
Epidemiology and Demographics
Risk Factors
Screening
Causes
Differentiating Small cell carcinoma of the lung from other diseases
Natural history, Complications, & Prognosis
Diagnosis
History and Symptoms | Physical Examination | Laboratory tests | Electrocardiogram | X Rays | CT | MRI Echocardiography or Ultrasound | Other images | Alternative diagnostics
Treatment
Medical therapy | Surgical options | Primary prevention | Secondary prevention | Financial costs | Future therapies
Prognostic factors
The pretreatment prognostic factors that consistently predict for prolonged survival include good performance status, female gender, and limited-stage disease. Patients with involvement of the central nervous system or liver at the time of diagnosis have a significantly worse outcome. In general, patients who are confined to bed tolerate aggressive forms of treatment poorly, have increased morbidity, and rarely attain 2-year disease-free survival; however, patients with poor performance status can often derive significant palliative benefit and prolongation of survival from treatment.
Regardless of stage, the current prognosis for patients with SCLC is unsatisfactory even though considerable improvements in diagnosis and therapy have been made during the past 10 to 15 years.
Related Chapters
External links
- Neuroimmunology - by Abid R Karim, Birmingham UK, at University of Birmingham Medical School
- Image at Tulane University